Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...
During trials of the wearable, WeaRo, which weighs roughly 11.5 lbs, muscle activation levels of lumbar, bicep and tricep muscles were reduced by 18.2%, 29.1% and 27.0%, respectively — and without ...